Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvakitug maintenance phase 3 study in moderately to severely active Crohn's disease
jRCT2031250581Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of duvakitug in Crohn's disease (4 arms), sponsored by Sanofi. Primary endpoints: Clinical remission by CDAI at Week 40, Endoscopic response by SES-CD at Week 40 and 2 more. Started Jul 2026; status: recruiting.
02
Drugs
duvakitug
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT2031250581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250581.